Arrowhead Pharmaceuticals

RNA strand
#Arrowhead Pharmaceuticals #Cardiovascular disease #Phase II trial #RNA therapy

Arrowhead’s RNA therapy silences two genes simultaneously

Arrowhead Pharmaceuticals has announced interim topline data from a Phase I/IIa clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia.   ARO-DIMER-PA is designed to silence expression of both… Read More

#News

Heart
#Arrowhead Pharmaceuticals #Cardiometabolic diseases #China #RNA #Sanofi

Sanofi buys Chinese rights to cardiometabolic drug candidate

Sanofi has bought the rights to Arrowhead Pharmaceuticals first-in-class RNA interference (RNAi) therapeutic candidate for hypertriglyceridemia in Greater China.  Under the agreement, Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead.  The investigational drug plozasiran is… Read More

#Business & Investment #News